<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857255</url>
  </required_header>
  <id_info>
    <org_study_id>R01DC018550</org_study_id>
    <nct_id>NCT04857255</nct_id>
  </id_info>
  <brief_title>Technology-assisted Language Intervention (TALI)</brief_title>
  <acronym>TALI</acronym>
  <official_title>Technology-assisted Language Intervention for Children Who Are Deaf/Hard-of-hearing (TALI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing the effectiveness of augmentative and alternative communication&#xD;
      technology among deaf or hard of hearing children for improving language development.&#xD;
      Children will be randomized to receive either the technology intervention or treatment as&#xD;
      usual&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Length of Utterance in morphemes</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measurement of syntax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Turn Length</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measurement of discourse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of different vocabulary words spoken</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure of semantics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Evaluation of Language Fundamentals-5th edition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Provides receptive and expressive standard scores on a scale with a mean of 100 +/- 15standard deviations; higher scores indicate better/higher language skills</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expressive Vocabulary Test 2nd edition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Provides expressive vocabulary standard scores on a scale with a mean of 100 +/- 15standard deviations; higher scores indicate better/higher vocabulary skills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Evaluation of Language Fundamentals-5th edition-pragmatics profile</measure>
    <time_frame>24 weeks</time_frame>
    <description>Provides pragmatic language scores as scaled scores (ranging from 1 to 15), age equivalents and percentile ranks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Hearing Loss, Bilateral</condition>
  <condition>Language Development</condition>
  <arm_group>
    <arm_group_label>Technology Assisted Language Intervention (TALI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentative and alternative communication software incorporated into active speech-language therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Speech language therapy child is typically receiving (no change to current care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Technology assisted language intervention</intervention_name>
    <description>speech language therapy that has integrated technology delivered through specific software on an iPad</description>
    <arm_group_label>Technology Assisted Language Intervention (TALI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treatment as usual</intervention_name>
    <description>No change will occur to the current ongoing speech-language therapy being delivered.</description>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 3-10 years&#xD;
&#xD;
          -  Documented permanent bilateral hearing loss with severity levels clinically defined&#xD;
             moderate to profound).&#xD;
&#xD;
          -  Identified with a language deficit, defined by either the ratio of language standard&#xD;
             scores to nonverbal intelligence quotient &lt;.85 or a differences in nonverbal IQ and&#xD;
             language standard scores of 10 points. Language scores may either be receptive or&#xD;
             expressive.&#xD;
&#xD;
          -  Currently receiving speech-language therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Mild hearing loss and unilateral hearing loss&#xD;
&#xD;
          -  primary language other than English&#xD;
&#xD;
          -  significant motor impairments&#xD;
&#xD;
          -  nonverbal IQ &lt;80&#xD;
&#xD;
          -  children with severe communication disorders (i.e. autism spectrum disorders).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jareen Meinzen-Derr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jareen Meinzen-Derr, PhD</last_name>
    <phone>513-636-7789</phone>
    <email>jareen.meinzen-derr@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Lane, MPH</last_name>
    <phone>5138031901</phone>
    <email>laura.smith1@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Mood, PhD</last_name>
      <phone>720-777-2778</phone>
      <email>Deborah.Mood@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jareen Meinzen-Derr, PhD</last_name>
      <phone>513-636-7789</phone>
      <email>jareen.meinzen-derr@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Smith, MPH</last_name>
      <phone>513-803-1901</phone>
      <email>laura.smith1@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Wiley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hearing loss</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>intervention</keyword>
  <keyword>language development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Bilateral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

